The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CIMAC-CIDC CyTOF harmonization.
 
Adeeb Rahman
No Relationships to Disclose
 
Bita Sahaf
No Relationships to Disclose
 
Melanie Davila
No Relationships to Disclose
 
Nicholas Fernandez
No Relationships to Disclose
 
Emily McWilliams
No Relationships to Disclose
 
Karen Millerchip
Research Funding - Idera; Iovance Biotherapeutics; Nektar
 
Salah E Bentebibel
No Relationships to Disclose
 
Cara L. Haymaker
Research Funding - Idera (Inst); Iovance Biotherapeutics (Inst); Nektar (Inst)
 
Natalia Sigal
No Relationships to Disclose
 
Caroline Duault
No Relationships to Disclose
 
Emily Thrash
No Relationships to Disclose
 
Diane Del Valle
No Relationships to Disclose
 
Beatriz Sanchez Espiridion
No Relationships to Disclose
 
Mina Pichavant
No Relationships to Disclose
 
Chantale Bernatchez
Stock and Other Ownership Interests - Lexicon (I); Myst Therapeutics
Consulting or Advisory Role - Myst Therapeutics
Research Funding - Dragonfly Therapeutics (Inst); EMD Serono; Idera; Iovance Biotherapeutics; MedImmune; Nektar; Pfizer
Patents, Royalties, Other Intellectual Property - Patent pending on BTLA as a marker for better CD8 T cells for adoptive immunotherapy
 
Ignacio Ivan Wistuba
Consulting or Advisory Role - AstraZeneca/MedImmune; Asuragen; Bayer; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Guardant Health; HTG Molecular Diagnostics; Merck; MSD Oncology; OncoCyte; Pfizer
Speakers' Bureau - MSD Oncology; Pfizer; Roche
Research Funding - 4D Molecular Therapeutics (Inst); Adaptimmune (Inst); Adaptive Biotechnologies (Inst); Akoya Biosciences (Inst); Amgen (Inst); Bayer (Inst); EMD Serono (Inst); Genentech (Inst); Guardant Health (Inst); HTG Molecular Diagnostics (Inst); Iovance Biotherapeutics (Inst); Johnson & Johnson (Inst); Karus Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); OncoPlex Diagnostics (Inst); Pfizer (Inst); Silicon Biosytems (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; GlaxoSmithKline; Guardant Health; HTG Molecular Diagnostics; MSD Oncology; Pfizer
 
Sacha Gnjatic
Consulting or Advisory Role - B4CC; Bristol-Myers Squibb; Merck; Neon Therapeutics; OncoMed; Third Rock Ventures
Research Funding - Agenus; Immune Design; Janssen; Pfizer; Regeneron; Takeda
Patents, Royalties, Other Intellectual Property - Patent on Multiplex Immunohistochemistry with Chromogen Staining on a Single Slide (MICSSS); Patents related to immune composition of NY-ESO-1 and peptides.
 
Sean Bendall
No Relationships to Disclose
 
Holden Maecker
Employment - Abbvie (I)
Stock and Other Ownership Interests - Abbvie (I)
Consulting or Advisory Role - Caris Life Sciences
Research Funding - Amgen; ION Pharma